Challenges and opportunities for development of an AIDS vaccine.
Among the devastating consequences of AIDS has been its epidemic spread in the developing world. The disease has caused unprecedented suffering, debilitation, loss of life and disruption of family, social and economic stability. Because of the considerable expense and logistical difficulty in providing antiviral drugs to populations infected with the human immunodeficiency virus throughout the world, the biomedical community is looking towards vaccines to help solve this compelling problem.
Nabel
G J
GJ
Vaccine Research Center, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3005, USA. gnabel@nih.gov
D016915:AIDS Vaccines / Q000276:immunology; D000276:Adjuvants, Immunologic; D000818:Animals; D006678:HIV / Q000276:immunology*; D015483:HIV Antibodies / Q000096:biosynthesis / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology; D015658:HIV Infections / Q000276:immunology* / Q000517:prevention & control*; D006801:Humans; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic
D016915:AIDS Vaccines; D000276:Adjuvants, Immunologic; D015483:HIV Antibodies; D015488:HIV Antigens; D014613:Vaccines, Attenuated; D014614:Vaccines, Synthetic